On this page, you will find different kinds of study results:
• A Lay summary which is a summary of clinical trial results written in an easy-to-understand way.
• A summary of results called synopsis which is written in scientific language. It is prepared for Medicines Agencies and Ethics Committees,
• A scientific publication which presents results for scientists and medical doctors.
218 Results
Protocol Code |
Study Title |
Active substance/Medical device |
Study Phase |
Therapeutic Area |
CL2-33138-011 |
A randomised, double-blind, placebo- and olanzapine- controlled, parallel-group study to evaluate the efficacy and safety…
|
S033138
|
Phase 2
|
Neuropsychiatric Diseases
|
|
CL2-33138-007 |
Safety and efficacy of S 33138 versus risperidone in schizophrenic patients with predominant positive symptoms:…
|
S033138
|
Phase 2
|
Neuropsychiatric Diseases
|
|
CL2-20098-075 |
Pharmacokinetics and safety of agomelatine in children (from 7 to less than 12 years) and…
|
AGOMELATINE, S020098
|
Phase 2
|
Neuropsychiatric Diseases
|
|
CL2-20098-072 |
Efficacy of agomelatine 25 mg/day (with possible increase to 50 mg/day after 8 weeks of…
|
AGOMELATINE, S020098
|
Phase 2
|
Neuropsychiatric Diseases
|
|
CL2-20098-067 |
Effect of agomelatine (25 mg) given orally once a day for 7 days on cerebral…
|
AGOMELATINE, S020098
|
Phase 2
|
Neuropsychiatric Diseases
|
|
CL2-20098-040 |
Efficacy and safety of Agomelatine (25 mg with potential adjustment at 50 mg) given orally…
|
AGOMELATINE, S020098
|
Phase 2
|
Neuropsychiatric Diseases
|
|
CL2-18986-009 |
Efficacy of 15 mg and 50 mg of S 18986 on cognitive symptoms in Mild…
|
S018986
|
Phase 2
|
Neuropsychiatric Diseases
|
|
CL2-18886-031 |
Effects of S 18886 on platelet function in type 2 diabetic patients treated by low-dose…
|
TERUTROBAN, S018886
|
Phase 2
|
Metabolism
|
|
CL2-18886-026 |
Effects of terutroban versus aspirin on composition of atherosclerotic plaque in patients undergoing a carotid…
|
TERUTROBAN, S018886
|
Phase 2
|
Cardiovascular Diseases
|
|
CL2-16257-101 |
Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients…
|
IVABRADINE, S016257
|
Phase 2
|
Cardiovascular Diseases
|
|
CL2-16257-099 |
Effects of ivabradine on vascular function in individuals at increased risk of developing cardiovascular disease…
|
IVABRADINE, S016257
|
Phase 2
|
Cardiovascular Diseases
|
|
CL2-16257-096 |
Effects of oral chronic administration of ivabradine (7.5 mg bid) in comparison to placebo (bid)…
|
IVABRADINE, S016257
|
Phase 2
|
Cardiovascular Diseases
|
|
CL2-16257-095 |
Effects of oral administration of ivabradine (7.5 mg bid) on post-ischaemic stunning induced by exercise…
|
IVABRADINE, S016257
|
Phase 2
|
Cardiovascular Diseases
|
|
CL2-16257-090 |
Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy…
|
IVABRADINE, S016257
|
Phase 2-3
|
Cardiovascular Diseases
|
|
CL2-16257-088 |
Effects of ivabradine IV versus placebo on haemodynamic parameters in patients with a low cardiac…
|
IVABRADINE, S016257
|
Phase 2
|
Cardiovascular Diseases
|
|
CL2-16257-073 |
Evaluation of the effects of oral administration of ivabradine 5 mg and 7.5 mg b.i.d.…
|
IVABRADINE, S016257
|
Phase 2
|
Cardiovascular Diseases
|
|
CL2-16257-062 |
Evaluation of the effects of 3 successive oral dosages (2.5, 5, 7.5 mg b.i.d.) of…
|
IVABRADINE, S016257
|
Phase 2
|
Cardiovascular Diseases
|
|
CL2-16257-060 |
Evaluation of the effects on heart rate, haemodynamic parameters, safety and tolerability of 5 mg…
|
IVABRADINE, S016257
|
Phase 2
|
Cardiovascular Diseases
|
|
CL2-16257-053 |
Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure
|
IVABRADINE, S016257
|
Phase 2
|
Cardiovascular Diseases
|
|
CL2-12911-039 |
A double-blind, multicenter, international randomised study to assess the effects of 4 month-oral administration of…
|
STRONTIUM RANELATE, S012911
|
Phase 2
|
Rheumatology
|
|
CL2-09490-157 |
Assessment of the effects on 24-hour ambulatory blood pressure and the safety of a once-a-day…
|
PERINDOPRIL TERT BUTYLAMINE, S009490
|
Phase 2
|
Cardiovascular Diseases
|
|
CL2-066913-002 |
A randomized, double blind, placebo-controlled, parallel, international multicenter study assessing the efficacy of S066913 in…
|
S066913
|
Phase 2
|
Cardiovascular Diseases
|
|
CL2-05985-005 |
Efficacy and safety of the fixed oral low-dose perindopril arginine 3.5 mg/amlodipine 2.5 mg combination…
|
AMLODIPINE, PERINDOPRIL ARGININE, S005985
|
Phase 2
|
Cardiovascular Diseases
|
|
CL2-05720-005 |
Efficacy and safety assessment of two schemes of oral administration of once-daily extended release metformin…
|
GLICLAZIDE, METFORMINE, S005720
|
Phase 2
|
Metabolism
|
|
CL2-05682-102 |
Impact of Daflon 500 mg on the progression of chronic venous disease and symptoms in…
|
MICRONISED PURIFIED FLAVONOID FRACTION, S005682
|
Phase 2
|
Cardiovascular Diseases
|
|
Servier clinical trials are mainly registered on
EU Clinical Trials Register
The EU Clinical Trials Register contains information on interventional clinical trials on medicines carried out in Europe, which started after 1 May 2004.
SEE MORE
ClinicalTrials.gov
Clinicaltrials.gov is a registry that contains information on clinical studies of human participants carried out around the world.
SEE MORE
ISRCTN registry
The International Standard Randomized Controlled Trial Number (ISRCTN) registry is a primary clinical trial registry recognised by World Health Organization (WHO) and International Committee of Medical Journal Editor (ICMJE) that accepts all clinical research studies.
SEE MORE